M. Gil Labrucherie's most recent trade in Septerna Inc. was a trade of 125,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Septerna Inc | Gil M. Labrucherie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2025 | 21,000 | 55,500 | - | 0 | Common Shares | |
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2025 | 12,000 | 12,000 | - | - | Director Stock Option (Right to Buy) | |
| Septerna Inc | Gil M. Labrucherie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 37,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 9,000 | 34,500 | - | 0 | Common Shares | |
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 5,000 | 5,000 | - | - | Director Stock Option (Right to Buy) | |
| Septerna Inc | Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.59 per share. | 25 Feb 2025 | 6,282 | 36,282 | - | 5.6 | 35,116 | Common Stock |
| Septerna Inc | Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.85 per share. | 25 Feb 2025 | 3,718 | 40,000 | - | 5.8 | 21,750 | Common Stock |
| Septerna Inc | Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.88 per share. | 19 Feb 2025 | 14,500 | 25,000 | - | 5.9 | 85,234 | Common Stock |
| Septerna Inc | Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.51 per share. | 19 Feb 2025 | 10,500 | 10,500 | - | 5.5 | 57,813 | Common Stock |
| Septerna Inc | Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.85 per share. | 19 Feb 2025 | 5,000 | 30,000 | - | 5.9 | 29,250 | Common Stock |
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2025 | 25,500 | 25,500 | - | 0 | Common Shares | |
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2025 | 15,000 | 15,000 | - | - | Director Stock Option (Right to Buy) | |
| Septerna Inc | Gil M. Labrucherie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 222,000 | 222,000 | - | - | Stock Option (Right to Buy) | |
| Acelyrin Inc | Gil M. Labrucherie | CFO and CBO | 31 Aug 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | ||
| Acelyrin Inc | Gil M. Labrucherie | CFO and CBO | 23 May 2024 | 184,042 | 184,042 | - | - | Employee Stock Option (right to buy) | ||
| Rezolute Inc | M. Gil Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 30,000 | 30,000 | - | - | Director Stock Option (Right to Buy) | |
| Acelyrin Inc | Gil M. Labrucherie | Chief Financial Officer | 09 Jan 2024 | 855,513 | 855,513 | - | - | Employee Stock Option (right to buy) | ||
| Acelyrin Inc | M. Labrucherie Gil | Chief Financial Officer | 04 Oct 2023 | 40,763 | 40,763 | - | 0 | Common Stock | ||
| Acelyrin Inc | Gil M. Labrucherie | Chief Financial Officer | 17 Aug 2023 | 254,939 | 254,939 | - | - | Employee Stock Option (right to buy) | ||
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2022 | 28,750 | 330,353 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 15 May 2022 | 17,448 | 312,905 (0%) | 0% | 4.0 | 68,920 | Common Stock |
| Rezolute Inc | Gil M. Labrucherie | Director | Purchase of securities on an exchange or from another person at price $ 3.80 per share. | 04 May 2022 | 52,631 | 53,572 | - | 3.8 | 199,998 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 10.95 per share. | 16 Feb 2022 | 7,579 | 301,603 (0%) | 0% | 10.9 | 82,990 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 94,000 | 94,000 | - | - | Stock Option | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 52,950 | 309,182 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 13.16 per share. | 16 Nov 2021 | 21,149 | 259,682 (0%) | 0% | 13.2 | 278,321 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 12.69 per share. | 16 Nov 2021 | 3,000 | 256,682 (0%) | 0% | 12.7 | 38,070 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2021 | 71,550 | 71,550 | - | - | Stock Option | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 13.83 per share. | 16 Aug 2021 | 7,867 | 243,231 (0%) | 0% | 13.8 | 108,801 | Common Stock |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 13.56 per share. | 16 Aug 2021 | 3,000 | 240,231 (0%) | 0% | 13.6 | 40,680 | Common Stock |
| Rezolute Inc | Gil M. Labrucherie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Nektar Therapeutics | Gil M. Labrucherie | SVP, COO & CFO | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 17 May 2021 | 7,898 | 251,098 (0%) | 0% | 18.3 | 144,533 | Common Stock |